Clinical trial links maca to better midlife well-being in postmenopausal women

A randomized trial published in Menopause found maca root was associated with lower anxiety, depression and sexual dysfunction scores in postmenopausal women, without meaningful hormone changes. Cubes, a wellness brand focused on intimacy, is pointing customers to the study as evidence that symptoms can shift even when standard lab results look normal.

Why it matters: - The trial suggests midlife symptoms tied to mood, desire and well-being may improve even when estrogen and androgen levels do not change. - The finding may matter for people who are told standard bloodwork is normal but still feel different. - Cubes is using the study to support maca-based wellness products aimed at desire, intimacy and relationships.

What happened: - A randomized, double-blind, placebo-controlled crossover trial of maca root was published in the peer-reviewed journal Menopause. - The study followed 14 postmenopausal women through separate six-week periods using maca and placebo. - At 3.5 grams per day, maca was linked to lower anxiety and depression scores and reduced sexual dysfunction on the Greene Climacteric Scale. - Blood work showed no meaningful change in estrogen or androgen activity that would explain the symptom shifts. - The researchers described the findings as preliminary.

The details: - Participants recorded better scores compared with both their own baseline and the placebo period. - The Greene Climacteric Scale is a standard menopause symptom questionnaire. - The study focused on symptom scores, not a broad medical treatment plan. - Cubes says it directs customers to the underlying research rather than asking them to accept product claims on faith. - Cubes also says maca fits within a longer tradition of plant compounds used before clinical research examined them. - The company says the trial was small and is not a substitute for medical advice.

Between the lines: - The result challenges a simple hormone-only explanation for midlife change. - If symptoms move independently of lab values, wellness discussions may need to weigh lived experience alongside bloodwork. - The study is not definitive because of its small sample size, but it adds a data point to a space often driven by anecdote and marketing. - Cubes is positioning itself as evidence-forward at a time when consumers are paying closer attention to whether wellness claims match the science.

What's next: - The maca findings will likely invite more research on whether the same pattern holds in larger groups. - Further studies would need to test whether the benefits are reproducible and how long they last. - Consumers and clinicians will likely keep watching for evidence that separates symptom relief from hormone changes.

The bottom line: - In a small clinical trial, maca improved several midlife well-being measures in postmenopausal women without clearly changing hormones, hinting that symptoms and standard lab results do not always move together.